Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia (NVDA) technology to either enhance their products ...
Johnson & Johnson’s medical technology unit and its health data company Verily have penned separate new deals with technology ...
Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to ...
Johnson & Johnson's Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population for plaque psoriasis.
Pharmaceutical Technology on MSN
ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory
J&J will now explore Rybrevant's efficacy and safety in a Phase III trial in first-line, EGFR-driven HNSCC and colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback